Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
VACH
VACH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VACH News
VERAXA Secures Financing to Advance Cancer Therapies Pipeline
2d ago
Newsfilter
VERAXA Biotech Secures $27.5 Million Financing Agreement
2d ago
Yahoo Finance
Voyager Acquisition's Merger with Veraxa Biotech Approved
Mar 13 2026
seekingalpha
VOYAGER ACQUISITION CORPORATION RECEIVES GREEN LIGHT FOR BUSINESS MERGER WITH VERAXA BIOTECH AG
Mar 13 2026
moomoo
VERAXA Biotech Merger with Voyager Approved by Shareholders
Mar 02 2026
Newsfilter
Shareholder Notice: M&A Class Action Firm Ongoing Investigation into the Merger Involving PBBK, VACH, LCTC, and SMLR
Nov 07 2025
Globenewswire
VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC
Jul 17 2025
Newsfilter
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Voyager Acquisition Corp. (NASDAQ: VACH)
Jul 17 2025
Globenewswire
VERAXA Biotech AG to Showcase Novel Cancer Therapies at Upcoming ASCO and BIO International Conventions
May 29 2025
NASDAQ.COM
VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform
May 29 2025
Newsfilter
VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer
May 20 2025
Newsfilter
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
May 05 2025
Yahoo Finance
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
May 05 2025
Newsfilter
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
Apr 23 2025
Newsfilter
Show More News
